Evidence map›Paper›PMID 41331414›Full record

ArticleBMC cancer2025

Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study.

Shui-Qing He, Shu-Hui Lv, Si-Qing Wen, Lin Wang, Ya-Hui Yu, Guo-Yi Zhang, Ding-Sheng Peng, Wei-Xin Bei, Chun-Lan Chen, Ze-Yu Zhao and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shui-Qing He *Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060.
Shu-Hui Lv *Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060.
Si-Qing WenDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060.
Lin WangDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060.
Ya-Hui YuDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Guo-Yi ZhangDepartment of Radiation Oncology, Cancer Center, the First People's Hospital of Foshan, Foshan, Foshan, 528000, China.
Ding-Sheng PengDepartment of Radiation Oncology, Huizhou Central People's Hospital, Huizhou, 516008, China.
Wei-Xin BeiDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060.
Chun-Lan ChenDepartment of Radiation Oncology, Cancer Center, the First People's Hospital of Foshan, Foshan, Foshan, 528000, China.
Ze-Yu ZhaoDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060.
Ying HuangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China. huangying@sysucc.org.cn.
Yan-Qun XiangDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060. xiangyq@sysucc.org.cn.
Guo-Ying Liu *Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060. liugy0109@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop a prognostic model that predicts outcomes and identifies ideal candidates for metastasis-directed therapy (MDT) in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) after chemo-immunotherapy and locoregional radiotherapy (LRRT).

methodsDm NPC patients receiving chemo-immunotherapy followed by LRRT across four centers were enrolled. Propensity score matching (PSM) analysis was conducted to compare progression-free survival (PFS) between patients who received MDT and those who did not. A predictive nomogram was developed to stratify patients and identify candidates for MDT.

resultsA total of 364 patients were included in this study. Of these, 94 patients received MDT, while 270 patients did not. PSM analysis revealed that MDT was associated with a significant PFS benefit (HR: 0.6; 95% CI, 0.38-0.93; p = 0.024). A prognostic nomogram was conducted based on three independent prognostic factors: posttreatment EBV DNA, age, and the number of metastatic lesions. In the low-risk group identified by the nomogram, patients receiving MDT exhibited significantly improved PFS compared to those who did not (median PFS, not reached vs. 37.8 months, p = 0.014). However, no significant difference was observed in the high-risk group (median PFS, 18.8 months vs. 13.7 months, p = 0.74).

conclusionMDT was associated with improved PFS in dm NPC patients, especially in those classified as low-risk.

Indexed as

ChemoradiotherapyNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisNomogramsPrognosisProgression-Free SurvivalPropensity ScoreRetrospective StudiesTreatment OutcomeChemo-immunotherapyDe novo metastatic nasopharyngeal carcinomaLocal regional radiotherapyMetastasis-directed therapy

Identifiers

PMID41331414
PMCPMC12673791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.